Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 37,732 shares, a drop of 20.8% from the December 15th total of 47,657 shares. Based on an average daily trading volume, of 76,246 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.7% of the shares of the company are sold short. Currently, 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 76,246 shares, the days-to-cover ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

GBIO has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Generation Bio in a report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Generation Bio in a research note on Friday, November 7th. Jefferies Financial Group lowered shares of Generation Bio from a “buy” rating to a “hold” rating and lowered their price target for the stock from $11.00 to $5.00 in a research report on Tuesday, December 16th. Wedbush set a $5.50 price objective on shares of Generation Bio and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Finally, Citigroup restated a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.88.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GBIO. Shay Capital LLC acquired a new stake in shares of Generation Bio during the 3rd quarter valued at $64,000. ADAR1 Capital Management LLC acquired a new stake in shares of Generation Bio during the third quarter worth $136,000. AQR Capital Management LLC purchased a new stake in shares of Generation Bio during the first quarter valued at $36,000. Cantor Fitzgerald L. P. acquired a new position in shares of Generation Bio in the 3rd quarter valued at $606,000. Finally, Marshall Wace LLP purchased a new stake in Generation Bio during the second quarter valued at about $37,000. Institutional investors own 95.22% of the company’s stock.

Generation Bio Stock Performance

Shares of NASDAQ:GBIO traded down $0.02 during trading on Friday, reaching $5.62. The company had a trading volume of 98,807 shares, compared to its average volume of 54,734. The firm’s fifty day moving average is $5.43 and its 200 day moving average is $5.43. The firm has a market capitalization of $37.87 million, a PE ratio of -0.60 and a beta of 2.05. Generation Bio has a twelve month low of $3.00 and a twelve month high of $10.40.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The firm had revenue of $1.59 million during the quarter, compared to the consensus estimate of $0.66 million. Equities analysts predict that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.